Cedric Francois - 20 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Executive Officer, Director
Signature
/s/ David Watson, attorney-in-fact for Cedric Francois
Issuer symbol
APLS
Transactions as of
20 Jan 2023
Net transactions value
-$492,029
Form type
4
Filing time
24 Jan 2023, 16:17:24 UTC
Previous filing
17 Jan 2023
Next filing
30 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Tax liability $492,029 -9,453 -0.9% $52.05 1,039,122 20 Jan 2023 Direct F1
holding APLS Common Stock 300,000 20 Jan 2023 Indirect Owner (The Francois Grossi Trust) F2
holding APLS Common Stock 234,411 20 Jan 2023 Indirect Owner (The Francois-DuBois Educational Trust) F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares withheld for tax on a restricted stock unit release.
F2 The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
F3 The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.